Sagent Pharmaceuticals, Inc. (SGNT) Reports Q4 Loss of $0.33, Offers FY12 Sales Guidance

Sagent Pharmaceuticals, Inc. (NASDAQ: SGNT) reported Q4 EPS of ($0.33), $0.22 worse than the analyst estimate of ($0.11). Revenue for the quarter came in at $48.5 million versus the consensus estimate of $45.51 million.

Sagent Pharmaceuticals, Inc. sees FY2012 revenue of $220-$250 million, versus the consensus of $234.1 million.

For earnings history and earnings-related data on Sagent Pharmaceuticals, Inc. (SGNT) click here.

---

Serious News for Serious Traders! Try StreetInsider.com Premium Free!

---

You May Also Be Interested In

• Jefferies sees a buying opportunity in this S&P 500 sector
• Aebi Schmidt Holding AG (AEBI) Reports Q2 results; offers guidance
• CorMedix (CRMD) Tops Q2 EPS by 6c; Offers Guidance